Imagine a treatment that doesn’t just ease the symptoms of ageing but resets old cells to a younger state. It sounds like science fiction, yet some of the world’s richest people are betting on it. Jeff Bezos, Peter Thiel, Yuri Milner and Sam Altman have all backed startups working on cellular reprogramming, one of the hottest ideas in longevity science.
What is cellular reprogramming?
As we age, our cells don’t just wear out. They also “forget” how to read their own genetic instructions properly. Reprogramming tries to remind them. Scientists briefly switch on a small set of genes that nudge a cell back toward a more youthful pattern, without turning it into a different kind of cell.
A simple way to picture it: an old computer that has slowed down because of clutter. Reprogramming is like a careful reset that clears the clutter but keeps all your files.
Why has it taken so long?
The idea has made old mice and monkeys healthier in the lab. But it had never been tried in people until this year. The risk is that wind back too far, and cells can lose their identity, which raises safety worries, including tumours. That is why the first human test is small, careful and focused on one organ.
The first human trial
The company behind it is Life Biosciences, and its treatment, called ER-100, targets glaucoma, an eye disease that damages the optic nerve and is a leading cause of blindness in older adults. The first patient was dosed in June 2026.
On 8 October 2026, the company shared early results from the first three participants:
- The treatment was well tolerated through the first 56 days, with no serious side effects reported.
- Two participants showed early signs of improvement in their field of vision.
- An independent safety board recommended moving to a higher dose.
Why you shouldn’t get carried away
This is genuinely a milestone, but it is very early.
- Only three people were included, and everyone knew they were receiving the treatment.
- The main goal is safety, not proving it works. The visual improvements are described as preliminary.
- The results come from the company. Independent confirmation in larger trials will be needed.
- It is a local treatment for the eye. It is a long way from a whole-body “age reversal” therapy.
The bottom line
For years, reprogramming was a promise made in mice. Now it has taken its first careful steps in people, and the early safety signs are encouraging. Whether it will actually restore sight, let alone slow ageing, will take years of larger trials to find out.
This article is general information, not medical or investment advice.
Source:
https://www.businessinsider.com/billionaires-cellular-reprogramming-longevity-it-may-work-2026-10
Transparency Note: This article was prepared with the assistance of artificial intelligence technologies. Every piece is thoroughly reviewed and verified by our editorial team, who retain full responsibility for the final content.
Picture: Gemini AI